PAD 135 Pill — YELLOW OVAL, 14mm — Hydrochlorothiazide

No photo available

Imprint	PAD / 135
Colour	YELLOW
Shape	OVAL
Size	14
Strength	Moexipril Hydrochloride 15 mg;Hydrochlorothiazide 25 mg
Dosage form	Tablet, Coated
Manufacturer	Paddock Laboratories, Inc.
NDC	0574-0135
Schedule	—
Availability	—
Ingredients	Moexipril Hydrochloride[Moexipril];Hydrochlorothiazide[Hydrochlorothiazide]

What does this imprint mean?

The imprint "PAD 135" is a code stamped or printed on the tablet or capsule by the manufacturer, used to identify the drug, its strength and the maker.

Active ingredient

Hydrochlorothiazide

Uses and warnings

Key warnings include: - "Use with caution in severe renal disease" as thiazides may precipitate azotemia - Caution advised with impaired hepatic function due to risk of hepatic coma - Risk of systemic lupus erythematosus exacerbation reported - "Lithium generally should not be given with diuretics" due to toxicity risk - Potential electrolyte imbalances requiring monitoring (hypokalemia, hyponatremia, hypochloremic alkalosis)

Hydrochlorothiazide is indicated for edema management associated with congestive heart failure, hepatic cirrhosis, and corticosteroid/estrogen therapy, as well as edema from renal dysfunction. It's also used to manage hypertension "either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs."

Read the full drug profile →